BPC
CCCC icon

Banque Pictet & Cie’s C4 Therapeutics CCCC Stock Holding History

Banque Pictet & Cie’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-20,000
Closed -$663K – 339
2020
Q4 		$663K Buy
+20,000
New +$580K 0.01% 255

Other funds holding CCCC

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Banque Pictet & Cie's CCCC Position: Q1 2021 in Review

Banque Pictet & Cie sold out of C4 Therapeutics (CCCC) in Q1 2021, closing a stake of 20,000 shares — an estimated $663K sold.

Banque Pictet & Cie first reported a position in CCCC in Q4 2020 and held it in 1 quarter. The position peaked at $663K in Q4 2020. 83 funds tracked by Wall St. Rank hold CCCC as of Q1 2021.

  • Banque Pictet & Cie reported no remaining C4 Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Banque Pictet & Cie sold 20,000 C4 Therapeutics shares in Q1 2021, an estimated $663K.
  • Banque Pictet & Cie first reported a position in C4 Therapeutics in Q4 2020 and held it in 1 quarter.
  • Banque Pictet & Cie's C4 Therapeutics position peaked at $663K in Q4 2020.
  • 83 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2021.

Based on Banque Pictet & Cie's 13F filing for Q1 2021, filed 11 May 2021.